查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1840577

甲状腺眼疾治疗市场按治疗类型、给药途径、类型、诊断、最终用户和分销管道划分－2025-2032年全球预测

Thyroid Eye Disease Treatments Market by Treatment Type, Route of Administration, Type, Diagnosis, End-User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，甲状腺眼疾治疗市场规模将达到 42.9 亿美元，复合年增长率为 6.09%。

主要市场统计数据
基准年 2024 26.7亿美元
预计年份：2025年 28.3亿美元
预测年份：2032年 42.9亿美元
复合年增长率 (%) 6.09%

本文介绍了推动甲状腺眼疾治疗领域重新获得关注和投资的临床、治疗和相关人员动态。

甲状腺眼疾（TED）的治疗模式已从以往的手术对症治疗模式转变为以标靶免疫疗法、先进诊断技术和整合式诊疗路径为主导的新时代。过去，该疾病主要采用皮质类固醇和矫正手术治疗，而如今，由于人们对自体免疫疾病、眼眶病变、甲状腺功能和眼部发炎之间相互作用的认识不断加深，该疾病再次引起临床医生的持续关注。这些科学进展正在改变临床实践模式、论文发表网络以及患者的期望。

随着患者寻求早期介入以维持生活品质和视力，临床医生正采取更积极的诊断方法。在那些优先考虑快速评估和协调治疗方案的中心，由内分泌科医生、眼科医生和眼整形外科医生组成的多学科团队正逐渐成为常态。同时，诊断技术的进步，例如更高解析度的眼眶影像和更便捷的血清学检测，正在帮助临床医生对疾病活动度进行分层，并调整治疗强度。

从支付者和政策制定者的角度来看，临床疗效、安全性以及治疗持久性的相互作用正在影响着医保报销的讨论和治疗路径的设计。随着治疗方法方案的多样化，临床决策正转向个人化演算法，这些演算法优先考虑患者报告的结局以及疾病控制的客观指标。这种转变为后续分析奠定了基础，组装了科学见解、临床协作和以病人为中心的照护如何重塑甲状腺眼疾（TED）的治疗生态系统。

治疗突破、诊断创新和医疗服务模式重组如何改变甲状腺眼疾的模式

过去几年，甲状腺眼疾（TED）的治疗发生了一系列变革，标誌着模式转移。治疗策略正从广泛的免疫抑制转向机制特异性调节，这主要得益于标靶生技药品和分子标靶疗法的出现。这种转变减少了对长期使用糖皮质激素的依赖，为活动性发炎患者提供了更多选择，并改变了手术介入时机的判断标准。

诊断技术的不断进步也在推动改变。先进的眼眶影像学技术和更精细的疾病活动评分能够实现更早、更准确的分期，并支持分层治疗方案。诊断精细度的提高使临床医生能够在发炎活动期选择全身治疗，并在病情稳定的慢性期放弃重组手术。同时，多学科诊疗模式的整合正在改善医疗服务的连续性，加快决策速度，并缩短从诊断到开始治疗的等待时间。

医疗服务模式也不断发展。门诊输液服务和门诊专科中心扩大了静脉和皮下治疗的覆盖范围，而远端医疗咨询则简化了长期追踪和症状监测。支付方框架和更新的指南日益强调循证的连续性护理，并支持那些能够持续改善患者功能和生活品质的干预措施。总而言之，治疗创新、诊断改进和护理模式重塑并非渐进式变革，而是结构性转变，它将改变疾病管理的轨迹和患者预后。

评估美国在2025年前宣布的关税措施对治疗药物供应链和成本结构的累积营运和商业性影响

预计2025年的关税调整和更广泛的贸易政策转变可能会影响与甲状腺眼疾（TED）治疗相关的药品、医疗设备和诊断设备的供应链经济。诸如特殊生技药品、输液装置、一次性耗材和高解析度成像设备等组件通常需要经过多个国际供应链节点，进口关税的变化可能会增加摩擦、前置作业时间和合规要求，供应商和製造商必须将这些因素纳入筹资策略中。

製造商可能会透过多元化生产基地、增加库存缓衝以及重新谈判供应商合约来应对关税带来的成本压力。在许多情况下，企业会加快近岸外包和在地化策略，以减轻关税的影响并降低运输相关的不确定性。虽然这些调整有助于稳定供应，但可能需要资本投资和营运重组，从而影响与医疗保健采购商的价格谈判和合约动态。

对于医疗服务提供者而言，直接影响可能包括进口治疗药物和诊断试剂的采购成本上升、资金配置更加紧张以及对医疗总成本的更加关注。支付者和医疗系统可能会加强对价值评估和事先核准的审查，以确保高成本疗法的合理性。同时，关税政策的调整可能会刺激本地製造业的倡议，并鼓励医疗设备和生技药品製造商与区域契约製造製造商合作，以在控製成本成长的同时维持病患的可及性。总体而言，2025年关税政策变化的累积影响将波及采购、生产策略和临床实施时间表，因此需要製造商、医疗服务提供者和政策制定者协调应对，以确保患者能够持续获得必要的治疗和诊断试剂。

关键细分洞察揭示了临床和商业层面的治疗决策管道、服务提供点和病人历程。

基于分割的视角阐明了治疗方式和临床环境如何相互作用以定义患者群体。治疗类型分为药物治疗和手术治疗，药物治疗包括皮质类固醇、免疫抑制剂、单株抗体、甲状腺激素控制和蛋白酪氨酸激酶抑制剂，而手术治疗包括眼睑手术、眼眶减压术和斜视手术。这种二分法凸显了许多患者采用组合方案后病情进展良好，且早期药物控制发炎可以减少后续重组手术的范围和复杂性。

给药途径会影响病人体验和服务提供方式。输液治疗通常需要配备输液设施的环境和训练有素的医护人员，而口服药物则需要在门诊进行管理，并需考虑患者的依从性。这些差异会影响治疗的实施地点以及医疗服务提供者为支持不断变化的治疗方案组合所需具备的运作能力。

将甲状腺眼疾 (TED) 分为 I 型和 II 型有助于预后判断和治疗方法方案选择，因为临床表型与眼眶受累、复视和压迫性视神经病变的可能性有关。从血液检查和影像学检查到眼眶超音波和放射性碘摄取试验等诊断方法，可以评估疾病的活动性和严重程度，指南临床医生优先选择全身免疫调节疗法、标靶生技药品标靶治疗或手术治疗。医院、门诊病人中心和专科诊所在跨学科协作、手术能力和输液服务方面各不相同。此外，包括线上和线下零售在内的分销管道会影响患者获得口服和外用药物的途径，进而影响製造商和经销商如何规划物流、患者援助计划和依从性倡议。了解这些相互关联的环节有助于相关人员设计符合实际临床诊疗模式的、有针对性的临床路径、营运投资和病患支援体系。

在全球市场中，甲状腺眼疾治疗、监管应对和护理服务因区域动态和独特需求而有所不同。

在美洲，人们高度重视综合性专科中心和新型治疗方法的快速临床应用，法律规范和报销管道也为及时获得先进疗法提供了支持。该地区的临床网络日益重视整合内分泌和眼部整形等多学科专家的诊疗模式，从而实现协调的医疗服务和简化的就诊流程。同时，对门诊输液基础设施和远端医疗能够覆盖主要城市中心以外的广大患者。

欧洲、中东和非洲是一个异质性很强的地区，各国在监管环境、报销标准和临床能力方面有显着差异。在许多欧洲市场，集中化的卫生技术评估和与支付方的谈判推动了对治疗效果的仔细评估，而一些中东和非洲市场则更注重能力建设以及影像和外科专家的诊疗。在整个全部区域，专科中心与社区医院之间的合作对于提高诊断速度和推广多学科诊疗模式至关重要。

亚太地区在先进医疗中心快速应用新技术的同时，也在新兴市场不断扩大应用范围。该地区强大的製造业生态系统和活性化的临床实验室活动支持全球研究参与，并加速新治疗方法的普及。同时，专家资源和影像资源的短缺，使得需要建立注重培训、论文发表网络和经济高效诊断的实用型医疗模式。在任何特定地区，TED诊断和治疗创新成果融入临床实践的速度，都将取决于当地的监管态度、支付方的优先事项以及医疗基础设施。

竞争对手和合作伙伴层面的洞察，重点在于影响甲状腺眼疾创新和商业化的策略定位、能力优势和伙伴关係模式。

TED生态系中的主要企业凭藉其治疗产品线、诊断平台和服务交付伙伴关係关係脱颖而出。一些企业专注于开发作用机制明确的靶向生技药品和小分子药物，以应对炎症驱动因素；而另一些企业则投资于设备创新和成像系统，以提高诊断准确性和分期精度。生物製药公司与专科诊所之间的合作加速了真实世界证据的生成，并为支付方围绕临床价值和长期疗效的讨论提供了支持。

建立强大的供应链韧性、患者援助计划和教育倡议的製造商将有助于提高药物的接受度和依从性，尤其对于需要复杂剂量和监测的疗法而言更是如此。与契约製造製造商和区域经销商建立策略联盟，有助于降低海关和物流风险，并实现本地化商业化。此外，投资于临床医生推广、研究者主导的研究和指南制定的公司，将在塑造标准治疗实践方面发挥重要作用。

整合诊断、治疗和数位诊疗路径的伙伴关係模式正逐渐成为竞争优势。那些透过数据共用平台、远端医疗追踪和结果追踪实现协同诊疗的公司，不仅能够展现单一干预措施的有效性，更能凸显其整体效益。整体而言，将卓越的临床水准、灵活的供应链和协作式商业化相结合的公司策略，是与临床相关人员和患者建立并维持长期合作关係的最有效途径。

为产业领导者提供行动建议，使其研发、商业策略和医疗服务投资与不断变化的临床需求和政策环境保持一致。

领导者应优先考虑将治疗方法创新与诊断检验和明确的临床定位相结合的综合开发项目。他们还可以纳入转化生物标誌物，以支持精准应用案例和标籤扩大策略。同时，投资于多学科团队培训和发展中心辐射式服务模式，将确保新治疗方法能够惠及都市区专科中心和社区医疗机构的患者。

为降低供应链和贸易政策风险，企业应增加供应商多元化，探索区域製造伙伴关係，并为关键零件维持策略库存缓衝。商业团队应制定弹性价格设定和合约模式，以反映支付方的证据要求和总医疗成本，并建立完善的病患支援服务，以最大限度地提高病患依从性和长期疗效。最后，企业应与指南制定机构、支付方和专业协会积极合作，使临床管道与新兴证据保持一致，并努力简化合适的准入管道。

透明的调查方法详细说明了资料来源、分析方法和检验程序，以确保甲状腺眼疾分析的严谨性和可重复性。

本研究结合了对临床专家、外科医生和支付方代表的定性访谈，以及对同行评审文献、监管申报文件和临床试验註册库的结构化二次检索，以三角验证治疗和诊断趋势。专家访谈提供了关于不同医疗机构中临床决策、发表模式和运营限制的背景信息，而二次检索则提供了关于作用机制、安全性特征和诊断性能特征的技术细节。

分析方法包括对定性输入进行主题编码、对不同临床表型的治疗方法进行比较评估，以及对供应链和政策影响进行情境评估。研究结果透过跨部门审查进行内部检验，以确保临床准确性并协调相关人员的观点差异。在适当情况下，针对有关推广驱动因素和营运限制的假设进行了敏感度检验。研究调查方法强调透明度、可重复性和实用性，使读者能够追溯结论的原始证据和专家意见。

对结论的全面审查为致力于改善甲状腺眼疾患者治疗效果的临床医生、製造商和政策制定者提供了战略意义。

甲状腺眼疾的治疗正处于曲折点，治疗的针对性、诊断的清晰度和整合式医疗模式为改善患者预后创造了新的机会。临床医生受益于不断扩充的治疗工具，能够早期疗育和优化治疗顺序；而製药企业则拥有了展现超越短期临床疗效的、以患者为中心的持续获益的途径。政策制定者和支付方在塑造医疗服务可及性方面发挥关键作用，他们应将报销与以金额为准的指标挂钩，这些指标用于评估功能恢復和生活品质的提高。

临床医生需要接受能够反映最新证据的训练和诊疗路径，而生产商必须优先考虑供应稳定性和真实世界证据的产生。医疗系统应投资于能够缩短从诊断到治疗延误时间的多学科模式。这些措施共同作用，可以加速患者体验和临床疗效的显着改善，确保科学进步能够转化为可及的、高品质的医疗服务，造福于患有这种复杂自体免疫疾病的患者。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 长期病患登记研究的替普鲁单抗真实世界疗效和安全性结果
  • 一种针对甲状腺眼疾眼眶纤维母细胞的新型小分子治疗方法
  • 生物相似药研发对TED单株抗体治疗成本可及性的影响
  • 先进影像生物标记在个人化甲状腺眼疾治疗患者分层中的作用
  • 口服抗发炎药物研发管线创新，旨在减少甲状腺眼疾治疗中对皮质类固醇的依赖性
  • 针对罕见眼科疾病（例如甲状腺眼疾）的加速核准管道，监管环境正在不断变化。

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

8. 甲状腺眼疾治疗市场（依治疗类型划分）

  • 治疗
    • 皮质类固醇
    • 免疫抑制剂
    • 单株抗体
    • 甲状腺激素控制
    • 蛋白酪氨酸激酶抑制剂
  • 手术治疗
    • 眼睑手术
    • 眼眶减压手术
    • 斜视手术

9. 甲状腺眼疾治疗市场（依给药途径划分）

  • 静脉
  • 口服
  • 局部的

第十章 甲状腺眼疾治疗市场（依类型划分）

  • 类型 I TED
  • II型TED

11. 依诊断分類的甲状腺眼疾治疗市场

  • 血液检查
  • 影像检查
  • 超音波
  • 放射性碘摄取试验

第十二章 依最终用户分類的甲状腺眼疾治疗市场

  • 医院
  • 门诊中心
  • 专科诊所

13. 甲状腺眼疾治疗市场（依通路划分）

  • 线下零售
  • 线上零售

第十四章 甲状腺眼疾治疗市场：依地区划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 甲状腺眼疾治疗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国甲状腺眼疾治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Abbott Laboratories
    • Amgen Inc.
    • AbbVie Inc.
    • ACELYRIN, INC.
    • argenx SE
    • Bausch & Lomb Incorporated
    • BioXpress Therapeutics SA
    • Cipla Limited
    • Dr. Reddy's Laboratories Ltd.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • Genmab A/S
    • GlaxoSmithKline PLC
    • H. Lundbeck A/S
    • Hetero Drugs Limited
    • Immunovant, Inc.
    • Intas Pharmaceuticals Ltd.
    • Johnson & Johnson Services Inc.
    • Lupin Limited
    • Merck KGaA
    • Novartis AG
    • Pfizer, Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Sling Therapeutics, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Viridian Therapeutics, Inc.
Product Code: MRR-033332D2AF77

The Thyroid Eye Disease Treatments Market is projected to grow by USD 4.29 billion at a CAGR of 6.09% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.67 billion
Estimated Year [2025] USD 2.83 billion
Forecast Year [2032] USD 4.29 billion
CAGR (%) 6.09%

A forward-looking introduction to the clinical, therapeutic, and stakeholder dynamics driving renewed attention and investment in Thyroid Eye Disease care

Thyroid Eye Disease (TED) has moved from a largely surgical and symptomatic care model toward an era shaped by targeted immunotherapies, refined diagnostics, and integrated care pathways. Historically treated with corticosteroids and corrective surgeries, the condition now attracts sustained clinical interest because of advances in understanding autoimmune drivers, orbital pathology, and the interplay between thyroid function and ocular inflammation. These scientific developments are changing practice patterns, referral networks, and patient expectations.

Patients increasingly seek earlier intervention to preserve quality of life and visual function, prompting clinicians to adopt a more proactive diagnostic posture. Multi-disciplinary teams that include endocrinologists, ophthalmologists, and oculoplastic surgeons are becoming the norm in centers that prioritize rapid assessment and coordinated treatment plans. Meanwhile, diagnostic improvements-such as higher-resolution orbital imaging and more accessible serologic testing-help clinicians stratify disease activity and tailor treatment intensity.

From a payer and policy perspective, the intersection of clinical efficacy, safety profile, and treatment durability is shaping reimbursement conversations and pathway design. As therapeutic options diversify, clinical decision-making is shifting toward personalized algorithms that prioritize patient-reported outcomes alongside objective measures of disease control. This introduction frames the subsequent analysis by highlighting how scientific insight, clinical collaboration, and patient-centered care are reconfiguring the TED treatment ecosystem.

How therapeutic breakthroughs, diagnostic innovations, and care-delivery reorganizations are creating transformative shifts across the Thyroid Eye Disease landscape

The past several years have seen a cascade of changes that collectively represent a paradigm shift for TED management. Therapeutically, the emergence of targeted biologics and molecularly informed interventions is redirecting treatment strategies away from broad immunosuppression toward mechanism-specific modulation. This transition reduces reliance on prolonged corticosteroid regimens and increases options for patients with active inflammatory disease, thereby changing the calculus for timing of surgical intervention.

Diagnostic sophistication also drives transformation. Advanced orbital imaging modalities and refined activity scoring enable earlier and more accurate staging, which supports stratified treatment pathways. The improved granularity of diagnostic information empowers clinicians to select systemic treatments for active inflammatory phases and reserve reconstructive procedures for stable, chronic presentations. Concurrently, integration of multidisciplinary clinics improves continuity of care and accelerates decision-making, reducing delays from diagnosis to treatment initiation.

Healthcare delivery models are evolving in step. Outpatient infusion services and ambulatory specialty centers expand access to intravenous and subcutaneous therapies, while telehealth consultations streamline longitudinal follow-up and symptom monitoring. Payer frameworks and guideline updates increasingly emphasize evidence-based sequenced care, favoring interventions that demonstrate durable improvement in function and quality of life. Taken together, therapeutic innovation, enhanced diagnostics, and care redesign are not incremental changes but structural shifts that alter the trajectory of disease management and patient outcomes.

Assessing the cumulative operational and commercial effects of prospective United States tariff policies announced for 2025 on therapy supply chains and cost structures

Anticipated tariff adjustments and broader trade policy shifts in 2025 have the potential to affect supply chain economics for medicines, medical devices, and diagnostic equipment associated with TED care. Components such as specialty biologics, infusion equipment, single-use disposables, and high-resolution imaging hardware often cross multiple international supply nodes, and changes in import duties can introduce added friction, lead-times, and compliance requirements that providers and manufacturers must incorporate into procurement strategies.

Manufacturers may respond to tariff-induced cost pressures by diversifying production footprints, increasing inventory buffers, or renegotiating supplier agreements. In many cases, firms will accelerate nearshoring or regionalization strategies to mitigate exposure to tariffs and to reduce transit-related uncertainty. These adjustments, while stabilizing supply, can require capital investment and operational retooling that influence pricing negotiations and contracting dynamics with healthcare purchasers.

For care providers, the immediate consequence can be higher acquisition costs for imported therapeutics and diagnostic capital, prompting tighter capital allocation and a greater emphasis on total cost of care. Payers and health systems may intensify value assessments and prior-authorization scrutiny to ensure appropriateness of high-cost interventions. At the same time, tariff-driven shifts can stimulate local manufacturing initiatives, encouraging partnerships between device or biologic producers and regional contract manufacturers to preserve access while controlling expense growth. Overall, the cumulative impact of tariff policy changes in 2025 will ripple across procurement, manufacturing strategy, and clinical adoption timelines, requiring coordinated responses from manufacturers, providers, and policymakers to sustain uninterrupted patient access to essential TED therapies and diagnostics.

Key segmentation insights that illuminate therapeutic decision pathways, service delivery points, and patient journeys across clinical and commercial dimensions

A segmentation-aware view clarifies how treatment modalities and clinical settings interact to define patient pathways. Treatment type divides into medical and surgical approaches, with medical options spanning corticosteroids, immunosuppressants, monoclonal antibodies, thyroid hormone control, and tyrosine kinase inhibitors, while surgical interventions include eyelid surgery, orbital decompression surgery, and strabismus surgery. This dichotomy highlights that many patients progress through combined regimens, where early medical control of inflammation can reduce the extent or complexity of subsequent reconstructive procedures.

Route of administration shapes both patient experience and service delivery. Intravenous therapies typically require infusion-capable settings and trained staff, oral agents facilitate ambulatory management and adherence considerations, and topical formulations offer localized symptom relief with lower systemic exposure. These differences influence where care is delivered and the operational capabilities required by providers to support evolving therapeutic mixes.

Disease classification into Type I and Type II TED informs prognosis and therapeutic selection because clinical phenotype correlates with orbital involvement and the likelihood of diplopia or compressive optic neuropathy. Diagnostic modalities-ranging from blood tests and imaging to orbital ultrasound and radioactive iodine uptake testing-enable disease activity and severity assessments that guide whether clinicians pursue systemic immunomodulation, targeted biologic therapy, or prioritize surgical correction. End-user segmentation further delineates delivery landscapes: hospitals, outpatient centers, and specialty clinics each offer varying degrees of multidisciplinary coordination, procedural capacity, and access to infusion services. Finally, distribution channels that include offline retail and online retail affect patient access to oral and topical agents and shape how manufacturers and distributors plan logistics, patient support programs, and adherence initiatives. Understanding these interconnected segments helps stakeholders design targeted clinical pathways, operational investments, and patient support mechanisms that reflect real-world care patterns.

Regional dynamics and localized imperatives driving differential adoption, regulatory response, and care delivery for Thyroid Eye Disease across global markets

The Americas exhibit a strong emphasis on integrated specialty centers and rapid clinical adoption of novel therapies where regulatory frameworks and reimbursement pathways support timely access to advanced treatments. Clinical networks in this region increasingly prioritize multidisciplinary clinics that combine endocrinology and oculoplastic expertise, enabling coordinated care and streamlined referral processes. Parallel investments in outpatient infusion infrastructure and telemedicine support broader geographic reach for patients outside metropolitan centers.

Europe, Middle East & Africa presents a heterogeneous landscape where national regulatory systems, reimbursement criteria, and clinical capacity vary widely. In many European markets, centralized health technology assessment and payer negotiation drive careful evaluation of therapeutic benefit, while several Middle Eastern and African markets focus on capacity building and access to diagnostic imaging and surgical expertise. Across this region, collaboration between specialist centers and regional hospitals is vital to improve diagnostic timeliness and to scale multidisciplinary approaches.

Asia-Pacific combines rapid adoption in advanced healthcare hubs with expanding access in emerging markets. Robust manufacturing ecosystems and growing clinical trial activity in the region support participation in global research and facilitated access to newer therapeutic modalities. At the same time, disparities in specialist availability and imaging resources necessitate pragmatic care models that emphasize training, referral networks, and cost-effective diagnostics. Across all regions, local regulatory posture, payer priorities, and healthcare infrastructure determine the pace at which innovations in TED diagnostics and therapeutics are integrated into routine clinical practice.

Competitive and collaborative company-level insights highlighting strategic positioning, capability strengths, and partnership models influencing Thyroid Eye Disease innovation and commercialization

Leading organizations in the TED ecosystem differentiate through therapeutic pipelines, diagnostic platforms, and service delivery partnerships. Some firms focus on advancing targeted biologics and small molecules with clear mechanisms of action that address inflammatory drivers, while others invest in device innovation and imaging systems to improve diagnostic accuracy and disease staging. Collaboration between biopharma companies and specialty clinics accelerates real-world evidence generation and supports payer discussions around clinical value and long-term outcomes.

Manufacturers that establish robust supply chain resilience, patient support programs, and education initiatives strengthen adoption and adherence, especially for therapies requiring complex administration or monitoring. Strategic alliances with contract manufacturers and regional distributors help mitigate tariff and logistics risks and enable localized commercialization. Additionally, companies that invest in clinician outreach, investigator-initiated research, and guideline development play an outsized role in shaping standard-of-care practices.

Partnership models that integrate diagnostics, therapeutics, and digital care pathways emerge as a differentiator. Firms that enable coordinated care through data-sharing platforms, telehealth-enabled follow-up, and outcomes tracking position themselves to demonstrate holistic benefits beyond single-intervention efficacy. Overall, company strategies that combine clinical excellence, supply chain agility, and collaborative commercialization offer the strongest pathway to durable engagement with clinical stakeholders and patients.

Actionable recommendations for industry leaders to align R&D, commercial strategy, and care-delivery investments with evolving clinical needs and policy environments

Leaders should prioritize integrated development programs that pair therapeutic innovation with diagnostic validation and clear clinical positioning. Designing trials that capture functional outcomes and patient-reported measures strengthens value propositions with clinicians and payers, while embedding translational biomarkers can support precision use-cases and label expansion strategies. At the same time, investing in training for multidisciplinary teams and developing hub-and-spoke service models ensures that new therapies reach patients in both urban specialty centers and regional care settings.

To mitigate supply chain and trade policy risks, organizations should expand supplier diversification, explore regional manufacturing partnerships, and maintain strategic inventory buffers for critical components. Commercial teams need to craft flexible pricing and contracting models that reflect payer evidence requirements and the total cost of care, and they should establish robust patient support services to maximize adherence and long-term outcomes. Finally, companies should pursue constructive engagement with guideline bodies, payers, and professional societies to align clinical pathways with emerging evidence and to streamline pathways for appropriate access.

Transparent research methodology detailing data sources, analytical approaches, and validation steps used to ensure rigor and reproducibility in the Thyroid Eye Disease analysis

The research synthesized primary qualitative engagements with clinical experts, surgeons, and payer representatives, combined with structured secondary review of peer-reviewed literature, regulatory filings, and clinical trial registries to triangulate therapeutic and diagnostic trends. Expert interviews provided contextual nuance on clinical decision-making, referral patterns, and operational constraints in different care settings, while secondary sources supplied technical details on mechanism of action, safety profiles, and diagnostic performance characteristics.

Analytical methods included thematic coding of qualitative inputs, comparative assessment of therapeutic modalities across clinical phenotypes, and scenario-based evaluation of supply chain and policy impacts. Findings underwent internal validation through cross-disciplinary review to ensure clinical fidelity and to reconcile differing stakeholder perspectives. Where appropriate, sensitivity checks were applied to assumptions about adoption drivers and operational constraints. The methodology emphasizes transparency, reproducibility, and pragmatic interpretation so readers can trace conclusions back to source evidence and expert input.

Concluding synthesis reinforcing the strategic implications for clinicians, manufacturers, and policymakers working to improve outcomes for patients with Thyroid Eye Disease

Thyroid Eye Disease care is at an inflection point where therapeutic specificity, diagnostic clarity, and integrated delivery models converge to create new opportunities for improved patient outcomes. Clinicians benefit from an expanded toolbox that enables earlier intervention and tailored treatment sequencing, while manufacturers have pathways to demonstrate durable, patient-centered benefits that extend beyond short-term clinical response. Policymakers and payers play a critical role in shaping access by aligning reimbursement with value-based metrics that capture functional recovery and quality-of-life improvements.

Sustained progress will depend on coordinated action: clinicians need training and care pathways that reflect evolving evidence; manufacturers must prioritize supply resilience and real-world evidence generation; and health systems should invest in multidisciplinary models that reduce delays from diagnosis to treatment. Together, these actions can accelerate meaningful improvements in patient experience and clinical outcomes, ensuring that advances in science translate into accessible, high-quality care for people living with this complex autoimmune condition.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Real-world efficacy and safety insights from long-term teprotumumab patient registries
  • 5.2. Emerging small molecule therapies targeting orbital fibroblasts in thyroid eye disease
  • 5.3. Impact of biosimilar development on cost accessibility of monoclonal antibody treatments for TED
  • 5.4. Role of advanced imaging biomarkers in stratifying patients for personalized TED therapy
  • 5.5. Pipeline innovation in oral anti-inflammatory agents reducing corticosteroid dependency in TED management
  • 5.6. Regulatory landscape evolution for expedited approval pathways in rare ophthalmic indications like TED

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Thyroid Eye Disease Treatments Market, by Treatment Type

  • 8.1. Medical Treatment
    • 8.1.1. Corticosteroids
    • 8.1.2. Immunosuppressants
    • 8.1.3. Monoclonal Antibodies
    • 8.1.4. Thyroid Hormone Control
    • 8.1.5. Tyrosine Kinase Inhibitors
  • 8.2. Surgical Treatment
    • 8.2.1. Eyelid Surgery
    • 8.2.2. Orbital Decompression Surgery
    • 8.2.3. Strabismus Surgery

9. Thyroid Eye Disease Treatments Market, by Route of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Topical

10. Thyroid Eye Disease Treatments Market, by Type

  • 10.1. Type I TED
  • 10.2. Type II TED

11. Thyroid Eye Disease Treatments Market, by Diagnosis

  • 11.1. Blood Test
  • 11.2. Imaging Test
  • 11.3. Orbital Ultrasound
  • 11.4. Radioactive Iodine Uptake Test

12. Thyroid Eye Disease Treatments Market, by End-User

  • 12.1. Hospitals
  • 12.2. Outpatient Centers
  • 12.3. Specialty Clinics

13. Thyroid Eye Disease Treatments Market, by Distribution Channel

  • 13.1. Offline Retail
  • 13.2. Online Retail

14. Thyroid Eye Disease Treatments Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Thyroid Eye Disease Treatments Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Thyroid Eye Disease Treatments Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Abbott Laboratories
    • 17.3.2. Amgen Inc.
    • 17.3.3. AbbVie Inc.
    • 17.3.4. ACELYRIN, INC.
    • 17.3.5. argenx SE
    • 17.3.6. Bausch & Lomb Incorporated
    • 17.3.7. BioXpress Therapeutics SA
    • 17.3.8. Cipla Limited
    • 17.3.9. Dr. Reddy's Laboratories Ltd.
    • 17.3.10. Eli Lilly and Company
    • 17.3.11. F. Hoffmann-La Roche AG
    • 17.3.12. Genmab A/S
    • 17.3.13. GlaxoSmithKline PLC
    • 17.3.14. H. Lundbeck A/S
    • 17.3.15. Hetero Drugs Limited
    • 17.3.16. Immunovant, Inc.
    • 17.3.17. Intas Pharmaceuticals Ltd.
    • 17.3.18. Johnson & Johnson Services Inc.
    • 17.3.19. Lupin Limited
    • 17.3.20. Merck KGaA
    • 17.3.21. Novartis AG
    • 17.3.22. Pfizer, Inc.
    • 17.3.23. Regeneron Pharmaceuticals, Inc.
    • 17.3.24. Sling Therapeutics, Inc.
    • 17.3.25. Teva Pharmaceutical Industries Ltd.
    • 17.3.26. Viridian Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. THYROID EYE DISEASE TREATMENTS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. THYROID EYE DISEASE TREATMENTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. THYROID EYE DISEASE TREATMENTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY THYROID HORMONE CONTROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY THYROID HORMONE CONTROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY THYROID HORMONE CONTROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY THYROID HORMONE CONTROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY THYROID HORMONE CONTROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY THYROID HORMONE CONTROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY EYELID SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY EYELID SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY EYELID SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY EYELID SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY EYELID SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY EYELID SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORBITAL DECOMPRESSION SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORBITAL DECOMPRESSION SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORBITAL DECOMPRESSION SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORBITAL DECOMPRESSION SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORBITAL DECOMPRESSION SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORBITAL DECOMPRESSION SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY STRABISMUS SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY STRABISMUS SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY STRABISMUS SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY STRABISMUS SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY STRABISMUS SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY STRABISMUS SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE I TED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE I TED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE I TED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE I TED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE I TED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE I TED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE II TED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE II TED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE II TED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE II TED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE II TED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE II TED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY BLOOD TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY BLOOD TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY BLOOD TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY BLOOD TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY BLOOD TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY BLOOD TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY IMAGING TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY IMAGING TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY IMAGING TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY IMAGING TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY IMAGING TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY IMAGING TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORBITAL ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORBITAL ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORBITAL ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORBITAL ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORBITAL ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORBITAL ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY OUTPATIENT CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY OUTPATIENT CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY OUTPATIENT CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY OUTPATIENT CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY OUTPATIENT CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY OUTPATIENT CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY OFFLINE RETAIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY OFFLINE RETAIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY OFFLINE RETAIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY OFFLINE RETAIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY OFFLINE RETAIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY OFFLINE RETAIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)

TAB